Netherlands-based AIKON Health Secures €1.2M In Seed Round

The round was led by the TTT Medtech fund, with additional support from the Brabant Development Agency (BOM), Brabant Startup Fonds (BSF), Rabo Innovation Loan (RIL), and TNO Ventures.

Harm de Vries, Director of TTT Medtech, says, “AIKON Health exemplifies how cutting-edge research at TNO can lead to impactful medtech solutions. Their wearable for heart failure monitoring is exactly the kind of clinically relevant innovation TTT Medtech is proud to support – turning science into better care at home.”

Albertien Greijdanus, Senior Investment Manager BOM, adds, “As BOM, we are excited to invest in AIKON Health, whose wearable technology directly addresses the critical need for continuous monitoring of heart failure patients as they transition from hospital to home. Their solution enables earlier intervention, reduces readmissions, and supports better, patient-centred care beyond the hospital setting.”

Heart failure affects over 15 million people in Europe, leading to frequent hospital stays. In the Netherlands alone, 30,000 heart failure patients are hospitalised each year, costing over €800 million in avoidable healthcare expenses.

Read Also - Amsterdam-Based Fastned Secures €34.7Million in Its Second Bond Issue

AIKON’s solution allows doctors to track patients’ vital signs remotely through stretchable skin patches made from medical-grade materials. These patches use dry electrode technology and TNO’s flexible electronics expertise offering continuous, comfortable monitoring from home.

The technology helps clinicians make better decisions without needing frequent hospital visits, making it a promising option for improving care and reducing costs in heart failure management.

AIKON Health is working towards securing FDA approval within a few years of its founding, which would allow the company to enter both European and U.S. healthcare markets.

The recent investment will support AIKON’s product development and early clinical validation as it moves closer to this goal.

Most of the funding will be used to advance its modular wearable system, which includes a chest sensor and an arm sensor designed for continuous monitoring of heart failure patients.

Thiru Kanagasabapathi, founder and CEO of AIKON Health, says, “We’re grateful to have the backing of such a committed and focused group of investors. This underscores the potential of medical technology emerging from the Brainport region and the strength of our innovation ecosystem. Their support accelerates our path towards FDA approval, an ambitious milestone we’re pursuing just a few years after founding.”

AIKON Health aims to reduce hospital readmissions for heart failure patients by at least 25%, tackling a major issue in healthcare.

The company is part of TNO Ventures’ broader mission to bring breakthrough technologies from the lab to the market.

TNO, one of the largest independent research organisations in the Netherlands and the EU, created TNO Ventures to help high-potential startups grow into global players. This supports the Dutch innovation ecosystem by turning research into real-world solutions.

About AIKON Health

AIKON Health, founded in 2023 by Thiru Kanagasabapathi as a spin-off from TNO, is developing a wearable device to remotely monitor heart failure patients. Co-founded by Sofia Hidalgo and Siam Gnana, the Eindhoven-based digital health startup aims to reduce hospitalisations caused by poor monitoring.